BRIEF published on 09/18/2024 at 07:05, 1 year 2 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 2 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 3 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 3 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 3 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 3 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 4 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 1 year 4 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 1 year 5 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 1 year 5 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 12/16/2025 at 19:25, 47 minutes ago Cypher Metaverse Inc. Announces Signing of Definitive Agreement for Acquisition
Published on 12/16/2025 at 18:00, 2 hours 12 minutes ago RTO SPA Terminated: Mumena Mushinge, Brian Chasala, Terra Metals Inc. and Terra Metals Limited Failed to Provide Necessary Due Diligence Information and Failed to File CSE Application
Published on 12/16/2025 at 14:30, 5 hours 42 minutes ago Worksport Launches Rivian R1T Pickup Truck Compatible Cover, SOLIS Solar Tonneau
Published on 12/16/2025 at 14:00, 6 hours 12 minutes ago QNX Embedded Technology Now Powering More Than 275 Million Vehicles on the Road
Published on 12/16/2025 at 14:00, 6 hours 12 minutes ago Loop Industries and Ester Industries' India Joint Venture Awards Detailed Engineering Contract to Toyo for Infinite Loop(TM) India
Published on 12/16/2025 at 18:30, 1 hour 41 minutes ago SIX Exchange Regulation approves delisting of u-blox registered shares and grants exemption from specific disclosure requirements
Published on 12/16/2025 at 17:32, 2 hours 39 minutes ago M&G Credit Income Investment Trust plc: Net Asset Value(s)
Published on 12/16/2025 at 18:53, 1 hour 18 minutes ago Number of shares and voting rights - November 2025 (In French only)
Published on 12/16/2025 at 18:10, 2 hours 1 minute ago Amundi crosses the statutory threshold of 2% upwards
Published on 12/16/2025 at 17:45, 2 hours 27 minutes ago Imerys-December-2025-information-share-capital-and-voting-rights-as-of-30-November-2025
Published on 12/16/2025 at 17:43, 2 hours 29 minutes ago Aéroports de Paris S.A - November 2025 traffic figures
Published on 12/16/2025 at 08:30, 11 hours 42 minutes ago Cie du Bois Sauvage: Buy back of own shares – week from 08/12/2025 to 12/12/2025
